Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Within the DNA damage response (DDR) network, p53 serves not only as a central transcriptional regulator but also as a critical determinant of tumor development and therapeutic response. More than 50% of human cancers harbor TP53 mutations; however, mutation status alone is insufficient to explain biological outcomes. Distinct mutation types may result in loss of function (LOF), partial loss of function, dominant-negative (DN) effects, or gain of function (GOF), each directly influencing drug sensitivity, resistance mechanisms, and synthetic lethality opportunities.
Built upon a systematic understanding of DDR biology and p53 functional complexity, Creative Biogene has developed a closed-loop platform spanning genomic mutation profiling, functional classification, pathway activity quantification, drug response prediction, and in vitro/in vivo validation. This integrated system supports the full continuum from target validation to candidate drug screening and provides a functional framework for informed decision-making in drug development.
Figure 1. Schematic representation of p53‑mediated DNA damage response. (Krishnaraj J, et al., 2023)
In clinical tumor samples, TP53 mutations exhibit substantial heterogeneity, and even identical hotspot mutations may lead to distinct biological consequences depending on cellular context. Accordingly, our analytical strategy progresses in a structured manner from molecular structure to protein function and ultimately to pathway-level output, ensuring continuity across all layers of interpretation.
Comprehensive analysis begins with high-resolution mutation detection. Full exon sequencing of TP53 ensures complete coverage of coding regions, with focused interrogation of well-characterized hotspot mutations (e.g., R175, R248, R273, R249, R282). In parallel, copy number variations, loss of heterozygosity (LOH), clonality, and tumor heterogeneity are evaluated to establish a robust genomic baseline.
This classification directly guides downstream strategy: LOF mutations are addressed via reactivation or synthetic lethality, while GOF mutations require targeting aberrant oncogenic functions.
In addition to TP53, our platform supports analysis within a broader DDR and p53-associated gene network, enabling context-dependent validation and screening:
Experimental models include CRISPR-engineered knockout/knock-in systems, patient-derived mutant cell lines, and customized cellular platforms tailored to project-specific requirements.
For programs focused on MDM2 inhibitors or p53 reactivation strategies, we provide dedicated assays to evaluate target interaction and pathway modulation:
This module enables precise discrimination between true hits and false positives while supporting mechanism-of-action optimization.
Drug screening is conducted through two complementary, mechanism-driven approaches aligned with p53 functional status:
Functional Restoration Screening
Applied to partially defective p53 mutants, this strategy evaluates conformational stability (thermal shift assays, protease sensitivity) and screens small-molecule libraries. Restoration of transcriptional activity is confirmed through reporter assays and endogenous target gene expression analysis.
Synthetic Lethality Screening
Designed for p53-null or complete LOF contexts, this approach identifies vulnerabilities dependent on p53 deficiency, focusing on targets such as ATR, WEE1, CHK1, and POLQ. Combination strategies are further evaluated to determine synergistic drug responses, including sensitivity to ATR and WEE1 inhibitors in p53-mutant models.
Both strategies can be deployed independently or in parallel, depending on project objectives.
All studies are conducted within Creative Biogene's BSL-2 laboratory environment under a robust internal quality management framework. Core infrastructure includes:
Creative Biogene provides a unified platform that connects molecular characterization with therapeutic strategy. The service framework is designed to:
For DDR-focused drug development programs or projects requiring deeper interpretation of TP53 mutations, this platform enables a transition from descriptive testing to actionable decision-making.
Creative Biogene can tailor p53 functional evaluation and drug screening strategies according to your project stage—from early discovery and mechanism validation to pre-IND development—balancing turnaround time, analytical depth, and cost efficiency.
How are drug screening strategies adapted to different p53 statuses?
Drug screening is not a one-size-fits-all process; the strategy is determined by p53 functional status. For partial-loss-of-function mutations, we prioritize evaluating small molecules for their ability to restore transcriptional activity. In p53-null or complete-loss backgrounds, the focus shifts to identifying dependency pathways and conducting synthetic lethality screens. For gain-of-function mutations, we target the aberrantly activated signaling networks. This tiered approach significantly improves screening efficiency and reduces unproductive experiments.
What kind of data and reports will be delivered?
Deliverables cover the entire chain from raw data to decision-ready recommendations. In addition to standard sequencing results and experimental readouts, we provide an integrated analysis report that includes mutation functional classification, pathway activity assessment, drug sensitivity predictions, and potential therapeutic strategy suggestions. All key experiments are accompanied by quality control parameters and method descriptions to facilitate internal review or regulatory submission.
Can the results support regulatory submission or companion diagnostic development?
Yes, but the level of support depends on project design. Our methodologies and data structures are aligned with translational research and companion diagnostic development requirements, including assay workflows, performance metrics, and cutoff recommendations. For projects with regulatory submission in mind, we can standardize methods from the design phase to facilitate future alignment with regulatory expectations.
How long does a typical project take?
Project timelines vary depending on the depth of analysis. Basic mutation profiling can be completed within a relatively short timeframe, while projects involving functional validation and drug screening require a longer schedule. Before project initiation, we provide a clear timeline based on your specific needs and keep you updated on key milestones throughout the execution.
Can you customize assays or models for specific mutations or drug programs?
Yes. In fact, most projects involve some degree of customization. Whether you need cell models engineered for specific TP53 mutations or a screening system tailored to your candidate compounds, we can modularly adjust assays, model systems, and data output formats to meet your requirements.
References:
Copyright © Creative Biogene. All rights reserved.